Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.35 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763755 | 0.95 | GRM2 (0.35) | L3MBTL1GRM2PTGESTP53MAPT | |
| SCHEMBL12763859 | 0.82 | RAB9A (0.39) | L3MBTL1GRM2PTGESTP53MAPT | |
| SCHEMBL29896863 | 0.82 | RAB9A (0.39) | L3MBTL1GRM2PTGESTP53MAPT | |
| SCHEMBL23302255 | 0.72 | HDAC11 (0.39) | L3MBTL1GRM2PTGESTP53MAPT | |
| SCHEMBL29896893 | 0.72 | HDAC11 (0.39) | L3MBTL1GRM2PTGESTP53MAPT | |
| SCHEMBL12763750 | 0.70 | CACNA1H (0.52) | PTGESCACNA1H | |
| SCHEMBL27162875 | 0.68 | PTGES (0.39) | GRM2PTGESTP53SMN1; SMN2CACNA1H | |
| SCHEMBL30046089 | 0.68 | PTGES (0.39) | GRM2PTGESTP53SMN1; SMN2CACNA1H | |
| SCHEMBL21949432 | 0.68 | TRPA1 (0.48) | DRD4 | |
| SCHEMBL30047210 | 0.68 | PTGES (0.40) | PTGESRAB9ACACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | L3MBTL1 3263/4885GRM2 4679/4885PTGES 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.